Equities research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research report issued on Monday. The firm set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Trading Up 12.5 %
Shares of BTX opened at $1.98 on Monday. The stock has a market capitalization of $116.48 million, a price-to-earnings ratio of -0.87 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The firm has a fifty day simple moving average of $2.17 and a 200 day simple moving average of $1.80.
About Brooklyn ImmunoTherapeutics
Recommended Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Insider Trading – What You Need to Know
- Garmin Navigates to New Highs Driven By Wearables Trend
- Stock Market Upgrades: What Are They?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- The How and Why of Investing in Gold Stocks
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.